Nasal and sinonasal inverted papilloma (NSIP) is a benign tumor in which surface epithelial cells grow downward into the underlying supportive tissue with varying degrees of metaplasia. Human papillomavirus (HPV) has been proposed as the causal agent in the pathogenesis of this disease. Many studies have shown that HPV can activate the Akt/mechanistic target of rapamycin (mTOR) signaling pathway, but the role of this pathway in HPV-associated NSIP is largely unknown. In this study, we enrolled 40 control tissue samples and 80 NSIP tissue samples. HPV genotyping showed that 47 of the 80 examined cases of NSIP were HPV-positive (58.8%), and the most common subtype was HPV11 (20/53, 37.7%). The immunohistochemistry showed statistically significant differences in phosphorylated Akt and phosphorylated S6 ribosomal protein staining among control samples, HPVpositive NSIP and HPV-negative NSIP. The HPV11 L1-L2 plasmid increased the proliferation of normal human nasopharyngeal epithelial NP69-SV40T cells and human nasopharyngeal cancer CNE1 cells. Meanwhile, rapamycin, an mTOR inhibitor, reversed the increased cell proliferation induced by the HPV11 L1-L2 plasmid. Western blot analysis showed that Akt/mTOR/S6 were overexpressed in NP69-SV40T cells and CNE1 cells infected with the HPV11 L1-L2 plasmid. These data demonstrate that HPV promotes cell proliferation through the Akt/mTOR signaling pathway in NSIP.
Introduction
Inverted papilloma (IP) is a type of tumor in which surface epithelial cells grow downward into the underlying supportive tissue with varying degrees of metaplasia. The bladder, urethra, renal pelvis, ureter, nose, and paranasal sinuses are all possible areas of IP occurrence [1] . When IP occurs in the nose or sinuses mucosa, patients may have signs and symptoms of nasal obstruction and epistaxis with headache or facial pain [2] . Nasal and sinonasal inverted papilloma (NSIP) is still controversial among pathologists and surgeons regarding its etiology, pathogenesis, and biological behavior. Risk factors for this disease include outdoor and industrial occupation; however, smoking and other inflammatory diseases such as allergic rhinitis and sinusitis are not considered etiologic factors [3, 4] . Although, NSIP is a benign epithelial growth originating from the basement membrane of the nasal cavity and paranasal sinus that inverts into the underlying stroma, its local invasiveness, high recurrence rate even after radical treatment, and malignant transformation make it difficult to treat [5] .
The etiology of NSIP is not sufficiently understood, although the human papilloma virus (HPV) has been implicated in its pathogenesis [6] [7] [8] [9] [10] [11] . Evidence of an etiological role for HPV in NSIP was first proposed in the late 1980s. Since then, major technological advances have increased the detection sensitivity of HPV; however, objective and definitive studies showing the association between HPV and NSIP remain sparse and this correlation is still the subject of debate. Widely disparate HPV detection rates in NSIP have been reported in the literature with a range of 0-72% and an average of~25% [1, 12] . Different experimental methods, such as in situ hybridization and polymerase chain reaction (PCR), either with type-specific probes or consensus probes, may explain this wide range of detection rates. Moreover, surrogate markers for HPV have not been comprehensively investigated, and no generally accepted immunohistochemical markers are currently available for this disease.
The mechanistic target of rapamycin (mTOR) contains 2549 amino acids and comprises several conserved structural domains, including the C-terminal domain which has strong homology to the catalytic domain of phosphoinositide 3-kinase (PI3K) [13, 14] . mTOR binds to other regulatory components, such as regulatorassociated protein of mTOR (Raptor) and G protein β subunit-like protein (GβL), to form the mechanistic target of the rapamycin complex 1 (mTORC1) [15] . Tuberous sclerosis complex 1 (TSC1) and TSC2 form a heterodimer complex to negatively regulate mTORC1 activity [16] . TSC2 phosphorylation mediated by AKT inhibits TSC2, releasing mTOR from repression for subsequent activation of downstream signaling cascades that modulate the protein translation of the ribosomal S6 protein kinase (S6K) and the eukaryotic initiation factor-binding protein 1 (4E-BP1) pathway [17] .
Recently, the PI3K/Akt/mTOR signaling pathway has been identified as an vital signaling cascade to modulate a diverse array of cellular processes including protein translation and synthesis, cellular metabolism, autophagy, and cell migration, leading to the genesis of many human cancers [18] . Many studies have suggested that HPV may activate the Akt/mTOR signaling pathway. Surviladze et al. [19] reported that the Akt/mTOR signaling pathway could be activated within several minutes of exposure to HPV16 pseudovirions in human keratinocytes. In addition, mTOR activation is frequently observed in most HPV-positive oropharyngeal cancers, HPV-positive head and neck squamous cell carcinoma (HNSCC), cervical squamous cell carcinoma, and cervical cancer squamous cell carcinoma (CCSCC) lesions and cell lines [20] [21] [22] [23] [24] . An international HNSCC tissue microarray analysis showed that activation of the mTOR pathway was observed in most HPV-positive HNSCC and CCSCC lesions and cell lines [24] . The analysis of 20 samples each of normal cervix, high-grade squamous intra-epithelial lesions (HSIL), and invasive SCCs also revealed the increased nuclear translocation of both pmTOR (Ser2448) and p70S6K (Thr389), indicating the constitutive activation and overexpression of the mTOR pathway in HSIL and SCC [25] . The data from these studies suggest that mTOR activation may play an important role in most HPV-induced cancers. However, there are no studies in the literature about the role of the Akt/mTOR signaling pathway in the development of NSIP.
In this study, we characterized the prevalence and distribution of HPV genotypes in NSIP and evaluated the association between the mTOR signaling pathway and HPV in NSIP to provide a theoretical and experimental basis for future studies focused on screening for diagnostic, predictive, and prognostic biomarkers for NSIP.
Material and Methods

Study group
The pathology database at Zibo Central Hospital (Shandong, China) from August 2005 to June 2017 was retrospectively reviewed, and a total of 120 control and NSIP cases were selected. The control group included 40 patients who had undergone septoplasty or mucotomy of the compensatory hypertrophied inferior turbinate. NSIP patients were identified using the search target 'IP' for exact matches. To ensure consistency of pathology and patient reporting, other Schneiderian papillomas such as fungiform papillomas and cylindrical/oncocytic papillomas were excluded. Two tissue microarray blocks containing 40 tissue samples from the control group and 80 NSIP tissue samples were created by manually reembedding archived paraffin-embedded tissues. All the patients signed an informed consent form prior to study participation. The characteristics of the subjects are summarized in Table 1 . All identifiers were removed to protect the patient's confidentiality. This study was approved by the Shandong University Medical Ethics Committee in accordance with the Declaration of Helsinki.
Cell culture
The normal human nasopharyngeal epithelial cell line NP69-SV40T and human nasopharyngeal cancer cell line CNE1 (American Type Culture Collection, Manassas, USA) were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Grand Island, USA) and RPMI-1640 (Invitrogen) culture medium respectively supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 U/ml streptomycin.
Plasmid construction and transfection
The plasmid construct expressing human HPV11 L1-L2 was prepared by cloning HPV11 L1 and HPV11 L2 DNA and pIRSE into the pCMV-Tag2B vector, and the DNA sequence was confirmed by DNA sequencing. For transient transfection, cells in 12-well collagencoated plates were transfected with the HPV11 L1-L2 plasmid construct with Lipofectamine 2000 (Invitrogen) at 37°C overnight (~20 h). A construct expressing GFP was routinely used in the experiment to visually monitor transfection efficiency, which was in the range of 60%-80%. Although the transfection efficiency varied between experiments, the variation within the experiments was small.
CCK-8 cell proliferation assay
Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8; Dojindo, Tokyo, Japan) according to the manufacturer's instructions. NP69-SV40T cells or CNE1 cells in the logarithmic phase of growth were seeded in 96-well plates at a density of 1 × 10 4 cells/well, and cultured in DMEM complete medium and RPMI-1640 culture medium respectively. After 24 h, cells were transfected with HPV11 L1-L2 plasmid and/or 10 nM rapamycin (Santa Cruz Biotechnology, Santa Cruz, USA). In addition, control cells were transfected with empty vector in DMSO. A total of 10 μl of Cell Counting Kit-8 reagent was added to each well, followed by incubation for 1 h at 37°C on 5 consecutive days, at the same time each day. Spectrometric absorbance at 450 nm was measured by an enzyme immunoassay analyzer (Bio-Rad Laboratories, Hercules, USA). All of the experiments were conducted in triplicate. 
HPV genotyping by HybriMax
Western blot analysis
Protein extracts of cultured NP69-SV40T cells and CNE1 cells were immunoblotted using the following antibodies: anti-pAkt(Ser473) antibody (1:1000 dilution), anti-Akt antibody (1:1000 dilution), anti-pmTOR(Ser2448) antibody (1:1000 dilution), anti-mTOR antibody (1:1000 dilution), anti-pS6(Ser235/236) antibody (1:1000 dilution), anti-S6 antibody (1:1000 dilution), and anti-β-actin antibody (1:2000 dilution) as previously described [26] . All these primary antibodies were from Cell Signaling Technology (Beverly, USA). Secondary antibodies conjugated to horseradish peroxidase were used for detection, followed by enhanced chemiluminescence (Santa Cruz Biotechnology) and autoradiography. Quantification of image density in pixel was performed by using the NIH Image J software (NIH, Bethesda, USA).
Immunohistochemical staining
Tissue microarray sections (4-μm thick) were dewaxed at 55°C for 30 min, and then subject to two washes for 15 min with xylene. Then the sections were rehydrated in a graded series of ethanol, followed by heat-induced epitope retrieval. Next, the tissues were treated with 3% H 2 O 2 and rinsed with 0.5% Tween-20/phosphate buffered saline (PBS). After incubation with 5% bovine serum albumin/ PBS for 30 min, the tissue sections were incubated at 4°C overnight with phospho-specific probes including primary antibodies against pS6 and pAkt, phosphorylated at their putative activation sites, Ser235/ 236 and Ser473 (Cell Signaling Technology), respectively. Each slide was treated with diluted biotinylated secondary antibody (Santa Cruz Biotechnology) for 30 min, and then rinsed with PBS. The substrate, DAB (3,3′-diamino-benzidine chromogen solution, EnVision + System Kit; Dako, Carpinteria, USA) was added to visualize positive expression. The slides were rinsed again and counterstained with Gill II hematoxylin, treated with xylene, and coverslipped. Negative control sections were immunostained as described above, but were incubated with PBS instead of primary antibody. Uterine cervical cancer tissues were used as a positive control. 
Tissue microarray analysis
Cells positively expressing pS6 and pAkt were identified by brown staining of the cell membrane or cytoplasm after reaction with the pS6 and pAkt antibody as previously described [27] . Cases in which no core was available or no epithelial cells were found were excluded. The pS6 and pAkt protein expression was semiquantified with regard to the intensity of cell staining (as '−' to '+++': '−' for negative staining if there was total absence of expression; score of '+', '++', or '+++' in order of ascending strength of positive staining) and the percentage of positive staining (of any intensity) in the total section (ranging from '−' to '+++': Grade '−' for <5% staining; Grade ' + ' for 5%-25%; Grade '++' for 26%-50%; and Grade '+++' for greater than 50%). Cell counting was repeated in five randomly selected microscopic fields at a 400× magnification. The pS6 and pAkt positive tissues were quantified based on intensity of positive cells × percentage of staining as showed in Table 5 .
Statistical analysis
Statistical analysis was performed using SPSS software (version 10.0) for the chi-squared test. The Kappa index was calculated to evaluate the accordance of the results. P < 0.05 indicated significant difference between groups.
Results
HPV genotype detection by HybriMax
To determine the role of the HPV virus in the pathogenesis of NSIP, the incidence of HPV in NSIP was investigated by HybriMax. Our study showed that HPV was detected in 47 of 80 (58.8%) NSIP ( Table 2) . HPV-positive NSIP consisted of 26/53 (49.1%) NSIP with no dysplasia or low-grade dysplasia, 18/23 (78.3%) NSIP with moderate to severe dysplasia, and 3/4 (75%) NSIP with SCC ( Table 3) . HPV was only detected in 3 of 40 (7.5%) controls in this study. The difference between the NSIP group and the control group was statistically significant (χ 2 = 28.8, P < 0.001). There was a significant difference between NSIP with no dysplasia or low-grade dysplasia and NSIP with moderate to severe dysplasia (χ 2 = 5.612, P = 0.018).
However, there were no statistically significant differences between NSIP with SCC and NSIP with no dysplasia or low-grade dysplasia, or NSIP with moderate to severe dysplasia (χ 2 = 1.002, P = 0.310, NSIP with SCC versus NSIP with no dysplasia or low-grade dysplasia; χ 2 = 0.02, P = 0.884, NSIP with SCC versus NSIP with moderate to severe dysplasia).
In the positive NSIP, both low-risk and high-risk genotypes were analyzed. A total of 47 HPV-positive samples were detected including 12 subtypes of HPV virus, which included six multiple infections of HPV virus (Fig. 1 ). There were five NSIP (9.43%) positive for HPV6, 20 positive for HPV11 (37.70%), seven positive for HPV16 (13.20%), four positive for HPV18 (7.54%), two positive for HPV33 (3.77%), two positive for HPV44 (3.77%), five positive for HPV52 (9.43%), one positive for HPV53 (1.89%), one positive for HPV56 (1.89%), two positive for HPV57 (3.77%), three positive for HPV58 (5.66%), and one positive for HPV68 (1.89%), as shown in Fig. 1 . In the positive NSIP, the most common subtype was HPV11 (37.7%), and the second most common was HPV16 (13.2%).
The expression of Akt/mTOR signaling pathway in the NSIP lesions
As a protein kinase, mTOR primarily functions in multiple cellular processes including cell proliferation, growth, differentiation, and survival. Many studies have shown that the Akt/mTOR signaling pathway is involved in HPV-mediated tumors. Thus, we examined the expression of pS6 and pAkt, which are the most effective downstream phosphorylation targets of mTORC1 and mTORC2 respectively, in NSIP. Representative histologic images demonstrate morphologic features of HPV-positive and HPV-negative NSIP and specific patterns of immunoreactivity of pS6 and pAkt (Fig. 2) . The intensity and the percentage of pS6 and pAkt staining are shown in Table 4 . Four samples were lost or unsatisfactory for study. Compared with the control non-neoplastic nasal mucosal tissue samples (8/38, 21.1%), pS6 was upregulated in the NSIP samples (18/31, 58.1%; 38/ 47, 80.9%) ( Fig. 2A and Table 5 ), and was found to be strongly expressed in both the cytoplasm and cytoplasmic membrane of the cells. As to pAkt, 10 of 38 (26.3%) non-neoplastic nasal mucosal tissue samples were positive, while pAkt was positive in 16 of 31 (51.6%) HPV-negative and 35 of 47 (74.5%) HPV-positive NSIP (Fig. 2B and Table 5 ). There were significant differences in pS6 and pAkt staining when comparing both groups of NSIP to non-neoplastic nasal mucosal tissue samples. Moreover, there were also significant differences in pS6 and pAkt staining between individual HPV-positive and HPV-negative NSIP ( Table 5 ). Most NSIP lesions showed highly elevated Akt/mTOR activity, indicating that the Akt/mTOR signaling pathway may be involved in HPV-mediated NSIP.
HPV11 L1-L2 increases cell proliferation and Akt/mTOR signaling pathway in NP69-SV40T cells and CNE1 cells
To further explore the role of the Akt/mTOR signaling pathway in HPV-mediated NSIP, we constructed a plasmid of HPV11, which was the most commonly infected virus according to our research. The plasmid, which was prepared by cloning HPV11 L1 DNA, HPV11 L2 DNA, and pIRSE into the pCMV-Tag2B vector, expressed the L1 and L2 capsid proteins of HPV11, and efficiently assembled into functional capsids. These infectious virions can mimic clinical HPV infections. It was found that the HPV11 L1-L2 plasmid increased the proliferation of NP69-SV40T cells and CNE1 cells in vitro in a time-dependent manner (Fig. 3A,B) , with maximal proliferation occurring on Day 5. Rapamycin, an inhibitor of mTOR, inhibited the increased cell proliferation induced by the HPV11 L1-L2 plasmid (Fig. 3C,D) . In addition, the HPV11 L1-L2 plasmid increased the protein expression of pAkt, pmTOR, and pS6 in the NP69-SV40T cells and CNE1 cells (Fig. 4A,B) . These results showed that the Akt/mTOR signaling pathway plays a pivotal role in the proliferation of HPV-mediated NSIP.
Discussion
The present study demonstrates that HPV promotes cell proliferation through the Akt/mTOR signaling pathway in NSIP. This conclusion was supported by the following observations: (i) HPV was detected in patients with NSIP, at a frequency of 58.8% (47/80); (ii) the most common subtype virus was HPV11; (iii) pS6 and pAkt protein expression was elevated in NSIP; (iv) HPV11 L1-L2 plasmid increased the proliferation of NP69-SV40T cells and CNE1 cells; (v) rapamycin reversed the increased cell proliferation induced by the HPV11 L1-L2 plasmid; and (vi) NP69-SV40T cells and CNE1 cells infected with the HPV11 L1-L2 plasmid had Akt/mTOR signaling pathway overexpression. Although the etiology of NSIP is not completely known, it is believed that HPV plays a significant role in the pathogenesis of NSIP [28, 29] . The etiological role of HPV in NSIP has been frequently studied since 1983, when HPV was first detected in NSIP [28, [30] [31] [32] . As shown in Table 2 , our results showed that the percentage of HPV detected by HybriMax in NSIP patients was 58.8%, which shows the role of HPV infection in this disease. This finding is in line with previous studies that detected HPV in NSIP [11, 33, 34] . A recent meta-analysis showed that the incidence of HPV is estimated to be~37.8% in NSIP worldwide [9] . Because, we used HybriMax, which is a sensitive and reliable assay for HPV detection and genotyping, the percentage of HPV detected in NSIP in our study was higher than the reported global average.
We also showed a statistical difference in HPV detection between NSIP and control samples (P < 0.01). There was a significant difference between NSIP with no dysplasia or low-grade dysplasia and NSIP with moderate to severe dysplasia. However, no statistically significant difference was shown between NSIP with SCC and NSIP with no dysplasia or low-grade dysplasia, or NSIP with moderate to severe dysplasia. The limited number of NSIP with SCC may account for the statistical results. HPV-positive NSIP was found in 49.1% (26/53) of NSIP with no dysplasia or low-grade dysplasia, 78.3% (18/23) of NSIP with moderate to severe dysplasia, and 75% (3/4) of NSIP with SCC. A metaanalysis showed that HPV was detected in 22.3%, 55.8%, and 55.1% of NSIP without dysplasia or carcinoma, NSIP with high-grade dysplasia, and NSIP with invasive SCC, respectively, which supports our results [12] . We also analyzed the distribution of HPV subtypes among the NSIP patients and found that the most common genotype in the NSIP lesions was HPV11, which is a low-risk type.
Although, HPV has been implicated in the development of NSIP, its role in the pathogenesis of NSIP has been the subject of debate. There have been a large number of studies on cell cycle regulators and tumor suppressor genes such as p53, p21, pRb, and p27 [6, 35, 36] . Moreover, some additional signaling pathways are equally important for HPV oncogene-transduced cells [37] . It is now widely accepted that HPV infection activates the Akt/mTOR signaling pathway by altering multiple molecular and cellular events to drive oncogenesis [19] . mTORC1 is activated in most HPV-associated SCCs, including oral and cervical carcinomas, as determined by the detection of accumulated pS6. Our results confirmed that HPV11 L1 and L2 expression caused an increase in cell proliferation and mTORC1 activity by activating phosphorylated mTOR and upregulating pS6 in NP69-SV40T cells and CNE1 cells. The significant differences in pAkt and pS6 staining between the HPV-positive and HPV-negative groups indicate that the Akt/mTOR signaling pathway may be involved in the development of HPV-mediated NSIP.
In conclusion, our study showed that the Akt/mTOR signaling pathway plays a pivotal role in HPV-mediated NSIP, and is critical to cell proliferation and tumor initiation. Thus, it has the potential to be exploited for therapeutic strategies.
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